Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04917796 · ClinicalTrials.gov registry record · NA

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

A NA study of Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
255
Enrollment target
6
Study locations

NCT04917796 is a NA study of Pain and Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 255 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (16% lower). The trial reports 6 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04917796, a NA study of Pain and Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
255 participants
Enrollment target
6
Study locations

Study Summary

This study is a randomized controlled trial of electroacupuncture (referred to as EA) versus sham acupuncture (referred to as EA) as effective treatments for Chemotherapy-Induced Peripheral Neuropathy (CIPN) pain in cancer survivors.

Interventions

  • OTHER Electroacupuncture
  • OTHER Sham Acupuncture

Study Locations (6)

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

New York

  • Memorial Sloan - Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2021-05-21
Est. Completion 2026-04-24
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04917796

The ClinicalTrials.gov registry entry for NCT04917796 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (16% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Electroacupuncture is the first listed.

NCT04917796 reports 6 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, New York, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04917796 about?

NCT04917796 is a clinical study titled "The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)". This study is a randomized controlled trial of electroacupuncture (referred to as EA) versus sham acupuncture (referred to as EA) as effective treatments for Chemotherapy-Induced Peripheral Neuropathy (CIPN) pain in cancer survivors.

What is the current status of trial NCT04917796?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 255 participants. The study started on 2021-05-21. Estimated completion is 2026-04-24.

What conditions does trial NCT04917796 study?

This clinical trial studies the following conditions: Pain, Chemotherapy-induced Peripheral Neuropathy, Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Nerve Pain.

What interventions are being tested in trial NCT04917796?

The interventions under investigation include: Electroacupuncture (OTHER), Sham Acupuncture (OTHER).

Who is sponsoring clinical trial NCT04917796?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04917796 being conducted?

This trial has 6 study locations across Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.